COVID-19: Partnership with Takeda and Novavax: 250 million vaccine production per year
COVID-19:
Takeda:
We have entered into a basic agreement to partner with “Novavax” and receive the technology to manufacture vaccines for new coronavirus.
Factory in Hikari City, Yamaguchi Prefecture:
Takeda prepares production facilities at its factory in Hikari City, Yamaguchi Prefecture.
We also received a grant of 30.1 billion yen from the Ministry of Health, Labor and Welfare.
The company plans to develop, manufacture, and distribute vaccines for Japan.
Secure production capacity:
The company has a production capacity of more than 250 million vaccines a year.
He hopes to get the first vaccine manufactured by the second half of next year and obtain national approval.
This is the first time that Takeda has partnered with a company for a new coronavirus vaccine.
NHK news
Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan
Takeda now has a vaccine project in its fight against the COVID-19 pandemic, alongside repurposing existing drugs and developing a plasma-based therapy to treat the deadly disease.
The Japanese pharma
reached a deal with Novavax to develop, manufacture and sell the U.S. biotech’s coronavirus vaccine candidate, NVX-CoV2373, in Japan.
While the exact monetary terms were not disclosed, the pair said Japan’s health authorities will help fund technology transfer, new infrastructure and scale-up of manufacturing. The goal is to build up capacity to produce 250 million doses of the shot a year.
“Takeda’s leading position in Japan, technical expertise, regulatory know-how and manufacturing capacity make the company an ideal partner to further expand the global availability of NVX‑CoV2373,” Novavax CEO Stanley Erck said in a statement.
RELATED: Novavax’s COVID-19 vaccine looks promising in early data
Data from the phase 1 portion of a phase 1/2 study
showed two consecutive doses of the recombinant shot triggered neutralizing antibodies at levels numerically higher than those seen in patients who had recovered from COVID-19.
A month ago, the Maryland biotech snared a $1.6 billion financial commitment from the U.S. government’s Operation Warp Speed to support the vaccine’s late-stage testing and manufacturing.
In return, the company pledged to deliver 100 million doses beginning as early as late 2020, with potentially more to come.
FiercePharma
https://www.fiercepharma.com/vaccines/novavax-takeda-team-up-to-introduce-covid-19-vaccine-to-japan